URUte Christine Rogner

Ute Christine Rogner

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ute Christine Rogner has a total of 149 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    BMAL2 controls adipose tissue inflammation and metabolic adaptation during obesity

    by Morgane A. Philippe, Blandine Fruchet, Lucie Cagninacci, Lucie Beaudoin, Alexis Gadault, Bastien Aznar, Nicolas Venteclef, Etienne Challet, Agnès Lehuen, Ute C. Rogner, et al.


  • Open Access

    BMAL2 controls adipose tissue inflammation and metabolic adaptation during obesity

    by Morgane A. Philippe, Blandine Fruchet, Lucie Cagninacci, Lucie Beaudoin, Alexis Gadault, Nicolas Venteclef, Etienne Challet, Agnès Lehuen, Ute C. Rogner, Amine Toubal

    Contemporary lifestyle modifications such as changes in nutritional and sleep/wake rhythms increase the risk of metabolic and inflammatory complications linked to obesity, including type 2 diabetes (T2D) and metabolic dysfunction-associated steatohepatitis (MASH). BMAL2 (Brain and Muscle ARNT Like Protein 2) is a transcription factor belonging to the circadian clock transcriptional feedback loop which synchronizes internal biological rhythms to environment. In humans, reduced expression in white adipose tissue (WAT) and specific polymorphisms of BMAL2 are associated with obesity and T2D. In this study we report that Bmal2 invalidation in mice leads to increased body weight gain during diet-induced obesity. Loss of BMAL2 triggers the inflammatory response by increasing Tnfα expression and modifying adipocyte progenitor fate. This results in reduced lipid storage capacity within the WAT and increased ectopic storage in the liver. These functional and structural alterations culminate in the onset of hepatic steatosis and insulin resistance in liver and WAT. Overall, our investigations underscore the role of BMAL2 in the development and function of adipocytes, as well as in their inflammatory potential within the WAT. Our findings contribute to the understanding of the role of circadian clock genes in obesity and interconnected metabolic complications. Highlights: The transcription factor BMAL2 is involved in metabolic complications of obesity in a mouse model of diet-induced obesity Invalidation of Bmal2 worsens insulin resistance and hepatic steatosis induced by high fat diet Invalidation of Bmal2 impairs visceral adipose tissue adaptation capacity in promoting inflammation and adipose progenitor decline Graphical

  • Open Access

    Deletion of the Clock GeneBmal2Leads to Alterations in Hypothalamic Clocks, Circadian Regulation of Feeding, and Energy Balance

    by Rosana Dantas-Ferreira, Dominique Ciocca, Patrick Vuillez, Stéphanie Dumont, Christian Boitard, Ute C. Rogner, Etienne Challet

    BMAL2 (ARNTL2) is a paralog of BMAL1 that can form heterodimers with the other circadian factors CLOCK and NPAS2 to activate transcription of clock and clock-controlled genes. To assess a possible role ofBmal2in the circadian regulation of metabolism, we investigated daily variations of energy metabolism, feeding behavior, and locomotor behavior, as well as ability to anticipate restricted food access in male mice knock-out forBmal2(B2KO). While their amount of food intake and locomotor activity were normal compared with wild-type mice, B2KO mice displayed increased adiposity (1.5-fold higher) and fasted hyperinsulinemia (fourfold higher) and tended to have lower energy expenditure at night. Impairment of the master clock in the suprachiasmatic nuclei was evidenced by the shorter free-running period (−14 min/cycle) of B2KO mice compared with wild-type controls and by a loss of daily rhythmicity in expression of intracellular metabolic regulators (e.g.,Lipoprotein lipaseandUncoupling protein 2). The circadian window of eating was longer in B2KO mice. The circadian patterns of food intake and meal numbers were bimodal in control mice but not in B2KO mice. In response to restricted feeding, food-anticipatory activity was almost prevented in B2KO mice, suggesting altered food clock that controls anticipation of food availability. In the mediobasal hypothalamus of B2KO mice, expression of genes coding orexigenic neuropeptides (includingNeuropeptide yandAgouti-Related Peptide) was downregulated, whileLipoprotein lipaseexpression lost its rhythmicity. Together, these data highlight that BMAL2 has major impacts on brain regulation of metabolic rhythms, sleep–wake cycle, and food anticipation.


  • Open Access

    Differential action of TIGIT on islet and peripheral nerve autoimmunity in the NOD mouse

    by Chantal Bécourt, Sandrine Luce, Ute Christine Rogner, Christian Boitard

    Summary: We previously demonstrated that the abrogation of the ICOS pathway prevents type 1 diabetes development in the Non Obese Diabetic (NOD) mouse, but results in a CD4 + T-cell dependent autoimmune neuromyopathy in aged mice. Pancreatic islet infiltrates in conventional NOD mice and neuromuscular infiltrates in Icosl -/- NOD mice have in common that they exhibit a strong enrichment in CD4 + TIGIT + T-cells, whilst TIGIT expression in the peripheral CD4 + T-cells is limited to the CD4 + FoxP3 + T-cell population. When deleting Tigit on the NOD background, diabetes incidence was found increased. Peripheral CD4 + CD226 + effector T-cells exhibited an increased frequency of IL-17 producing CD4 + CD226 + RORgt + T-cells versus a decreased frequency of IFNγ-producing CD4 + CD226 + Tbet + T-cells. ICOS is expressed in both CD4 + FoxP3 + and CD4 + CD226 + splenic T-cell subsets. Icosl deletion leads to a decrease of CD4 + FoxP3 + cells, with decrease of PD1 but increase of ICOS and CCRX3. Also in the Icosl -/- model, CD4 + CD226 + T-cells are decreased by Tigit deletion, and showed an increase of CD4 + CD226 + RORgt + T-cells and a decrease of CD4 + CD226 + Tbet + T-cells. However, deletion of Tigit in aged Icosl -/- NOD mice population did not increase the incidence of the autoimmune neuromyopathy observed in Icosl -/- NOD mice. Interestingly, the upregulation of CD4 + CD226 + RORgt + T-cells was partly rescued. We conclude from our study that both Icosl and Tigit deletions on the NOD background lead to a shift between the ratio of IFNγ and IL-17-producing CD4 + CD226 + effector cells. The ICOS-dependent neuromyopathy development remains dominant and is not further altered in the absence of TIGIT.

  • Open Access

    Differential action of TIGIT on islet and peripheral nerve autoimmunity in the NOD mouse

    by Chantal Bécourt, Sandrine Luce, Ute C Rogner, Christian Boitard

    We previously demonstrated that the abrogation of the ICOS pathway prevents type 1 diabetes development in the Non Obese Diabetic (NOD) mouse, but results in a CD4+ T-cell dependent autoimmune neuromyopathy in aged mice. Pancreatic islet infiltrates in conventional NOD mice and neuromuscular infiltrates in Icosl-/- NOD mice have in common that they exhibit a strong enrichment in CD4+TIGIT+ T-cells, whilst TIGIT expression in the peripheral CD4+ T-cells is limited to the CD4+FoxP3+ T-cell population.When deleting Tigit on the NOD background, diabetes incidence was found increased. Peripheral CD4+CD226+ effector T-cells exhibited an increased frequency of IL-17 producing CD4+CD226+RORgt+ T-cells versus a decreased frequency of IFN$γ$-producing CD4+CD226+Tbet+ T-cells. ICOS is expressed in both CD4+FoxP3+ and CD4+CD226+ splenic T-cell subsets. Icosl deletion leads to a decrease of CD4+FoxP3+ cells, with decrease of PD1 but increase of ICOS and CCRX3. Also in the Icosl-/- model, CD4+CD226+ T-cells are decreased by Tigit deletion, and showed an increase of CD4+CD226+RORgt+ T-cells and a decrease of CD4+CD226+Tbet+ T-cells.However, deletion of Tigit in aged Icosl-/- NOD mice population did not increase the incidence of the autoimmune neuromyopathy observed in Icosl-/- NOD mice. Interestingly, the upregulation of CD4+CD226+RORgt+ T-cells was partly rescued.We conclude from our study that both Icosl and Tigit deletions on the NOD background lead to a shift between the ratio of IFN$γ$ and IL-17-producing CD4+CD226+ effector cells. The ICOS-dependent neuromyopathy development remains dominant and is not further altered in the absence of TIGIT.

    • 22 November 2023
    • Published by HAL in HAL
    Open Access

    Differential action of TIGIT on islet and peripheral nerve autoimmunity in the NOD mouse

    by Chantal Bécourt, Sandrine Luce, Ute Rogner, Christian Boitard

    Raw data and statistical analysis can be obtained from the corresponding author.

  • Open Access

    The Spontaneous Autoimmune Neuromyopathy in ICOSL−/− NOD Mice Is CD4+ T-Cell and Interferon-γ Dependent

    by Claire Briet, Gwladys Bourdenet, Ute C. Rogner, Chantal Becourt, Isabelle Tardivel, Laurent Drouot, Christophe Arnoult, Jean-Claude Do Rego, Nicolas Prevot, Charbel Massaad, et al.

    Abrogation of ICOS/ICOS ligand (ICOSL) costimulation prevents the onset of diabetes in the NOD mouse but, remarkably, yields to the development of a spontaneous autoimmune neuromyopathy. At the pathological level, ICOSL-/-NOD mice show stronger protection from insulitis than their ICOS-/- counterparts. Also, the ICOSL-/-NOD model carries a limited C57BL/6 region containing the icosl nul mutation but, in contrast to ICOS-/-NOD mice, no gene variant previously reported as associated to NOD diabetes. Therefore, we aimed at providing a detailed characterization of the ICOSL-/-NOD model. The phenotype observed in ICOSL-/-NOD mice is globally similar to that observed in ICOS-/- and ICOS-/-ICOSL-/- double knockout NOD mice, manifested by a progressive locomotor disability first affecting the front paws as observed by catwalk analysis, and a decrease in grip test performance. The pathology remains limited to peripheral nerve and striated muscle. The muscle disease is characterized by myofiber necrosis/regeneration and an inflammatory infiltrate composed of CD4+T-cells, CD8+T-cells and myeloid cells, resembling human myositis. Autoimmune neuromyopathy can be transferred to NOD.scid recipients by CD4+ but not by CD8+T-cells isolated from 40-week-old female ICOSL-/-NOD mice. The predominant role of CD4+T-cells is further demonstrated by the observation that neuromyopathy does not develop in CIITA-/-ICOSL-/-NOD in contrast to β2microglobulin-/-ICOSL-/-NOD mice. Also, the cytokine profile of CD4+T-cells infiltrating muscle and nerve of ICOSL-/-NOD mice is biased toward a Th1 pattern. Finally, adoptive transfer experiments show that diabetes development requires expression of ICOSL, in contrast to neuromyopathy. Altogether, the deviation of autoimmunity from the pancreas to skeletal muscles in the absence of ICOS/ICOSL signaling in NOD mice is strictly dependent on CD4+T-cells, leads to myofiber necrosis and regeneration. It provides the first mouse model of spontaneous autoimmune myopathy akin to human myositis.


  • Open Access

    Loss of immune tolerance to IL-2 in type 1 diabetes

    by Louis Pérol, John M. Lindner, Pamela Caudana, Nicolas Gonzalo Nunez, Audrey Baeyens, Andrea Valle, Christine Sedlik, Delphine Loirat, Olivier Boyer, Alain Créange, et al.

    Type 1 diabetes (T1D) is characterized by a chronic, progressive autoimmune attack against pancreas-specific antigens, effecting the destruction of insulin-producing β-cells. Here we show interleukin-2 (IL-2) is a non-pancreatic autoimmune target in T1D. Anti-IL-2 autoantibodies, as well as T cells specific for a single orthologous epitope of IL-2, are present in the peripheral blood of non-obese diabetic (NOD) mice and patients with T1D. In NOD mice, the generation of anti-IL-2 autoantibodies is genetically determined and their titre increases with age and disease onset. In T1D patients, circulating IgG memory B cells specific for IL-2 or insulin are present at similar frequencies. Anti-IL-2 autoantibodies cloned from T1D patients demonstrate clonality, a high degree of somatic hypermutation and nanomolar affinities, indicating a germinal centre origin and underscoring the synergy between cognate autoreactive T and B cells leading to defective immune tolerance.


  • The circadian gene Arntl2 on distal mouse chromosome 6 controls thymocyte apoptosis

    by Basile Lebailly, Francina Langa, Christian Boitard, Philip Avner, Ute Christine Rogner

    Nonobese diabetic (NOD) mice are a model for type 1 diabetes that displays defects in central immune tolerance, including impairment of thymocyte apoptosis and proliferation. Thymocyte apoptosis is decreased in NOD/Lt mice compared to nondiabetic C3H/HeJ and C57BL/6 mice. Analysis of a set of NOD.C3H and NOD.B6 congenic mouse strains for distal chromosome 6 localizes the phenotype to the 700 kb Idd6.3 interval. Idd6.3 contains the type 1 diabetes candidate gene aryl hydrocarbon receptor nuclear translocator-like 2 (Arntl2), encoding a circadian rhythm-related transcription factor. Newly generated Arntl2−/− mouse strains reveal that inactivation of the B6 allele of Arntl2 is sufficient to both decrease thymocyte apoptosis and proliferation. When expressed from C3H or B6 alleles, ARNTL2 inhibits the transcription of interleukin 21 (Il21), a major player in the regulation of immune responses. IL-21 injection abolishes the B6 allele-mediated decrease of apoptosis and proliferation. Interestingly, IL-21 also leads to an increase in thymic proinflammatory Th17 helper cells. Our results identify Arntl2 as a gene controlling thymocyte apoptosis and proliferation along with Th17 development through the IL-21 pathway.


  • Circadian rhythm‐related genes: implication in autoimmunity and type 1 diabetes

    by B. Lebailly, C. Boitard, U. C. Rogner

    Recent gene association and functional studies have proven the implication of several circadian rhythm‐related genes in diabetes. Diabetes has been related to variation in central circadian regulation and peripheral oscillation. Different transcriptional regulators have been identified. Circadian genes are clearly implicated in metabolic pathways, pancreatic function and in type 2 diabetes. Much less evidence has been shown for the link between circadian regulation and type 1 diabetes. The hypothesis that circadian genes are involved in type 1 diabetes is reinforced by findings that the immune system undergoes circadian variation and that several autoimmune diseases are associated with circadian genes. Recent findings in the non‐obese diabetic mouse model pinpoint to specific mechanisms controlling type 1 diabetes by the clock‐related gene Arntl2 in the immune system.